The Food and Drug Administration's Oncologic Drugs Advisory Committee recommended approval of Puma Biotechnology Inc.'s (Nasdaq: PBYI) breast cancer treatment neratinib. Shares of the biopharmaceutical leaped $17.15 to close at $74.95
Approval recommended for Puma Biotechnology's neratinib
May 24, 2017 at 17:26 PM EDT
